Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

@article{Rasmussen2016ShockingHO,
  title={Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?},
  author={Thomas Aagaard Rasmussen and Sharon R Lewin},
  journal={Current opinion in HIV and AIDS},
  year={2016},
  volume={11 4},
  pages={
          394-401
        }
}
PURPOSE OF REVIEW To provide an overview of the initial experiences with the use of latency-reversing agents (LRAs) in clinical trials in HIV and to discuss and contrast results arising from these studies. RECENT FINDINGS Although the clinical administration of histone deacetylase inhibitors (HDACis) and disulfiram to HIV-infected individuals on antiretroviral therapy significantly increased cell-associated HIV RNA in CD4 T cells and in some cases plasma HIV RNA, this did not reduce the… CONTINUE READING

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Nanotechnology approaches to eradicating HIV reservoirs

  • European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

  • The Journal of clinical investigation
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Developing and applying ultrasensitive p 24 protein immunoassay for HIV latency

HC Yang, S Xing, L Shan
  • HIV Persistence during Therapy
  • 2015